A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension

Trial Profile

A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Fimasartan (Primary) ; Olmesartan medoxomil; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms FAST
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 03 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top